For research use only. Not for therapeutic Use.
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19)[1][2].
IC50 of SHEN26 (ATY014) against variants of beta and delta are 1.12 μM and 0.35 μM[1].
| Catalog Number | I040127 |
| CAS Number | 2691076-98-7 |
| Synonyms | [(2R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl cyclohexanecarboxylate |
| Molecular Formula | C19H23N5O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23N5O5/c20-9-19(14-7-6-12-17(21)22-10-23-24(12)14)16(26)15(25)13(29-19)8-28-18(27)11-4-2-1-3-5-11/h6-7,10-11,13,15-16,25-26H,1-5,8H2,(H2,21,22,23)/t13-,15?,16+,19+/m1/s1 |
| InChIKey | NJZZWWHRMAGFGB-TVMOFBLASA-N |
| SMILES | C1CCC(CC1)C(=O)OCC2C(C(C(O2)(C#N)C3=CC=C4N3N=CN=C4N)O)O |
| Reference | [1]. Chen Q, et al. Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19. Organic Process Research & Development. 2023 Nov 20. [2]. Ji X, et al. Research and development of Chinese anti-COVID-19 drugs. Acta Pharm Sin B. 2022 Dec;12(12):4271-4286. |
